Open in app

A new study suggests a novel effective combination therapy for children with T-acute leukaemia.

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:
(Image Courtesy: - Frontiers) 

The findings are based on a previous study by Tampere University's research group, which found that dasatinib, a generic tyrosine kinase inhibitor, was effective in around one-third of the patient samples tested. Because a single medicine's efficacy in the treatment of leukaemia wears off quickly, the present study explored for pharmacological combinations that may have a larger synergistic effect with dasatinib. This was the case with the drug temsirolimus, which inhibits a different signalling pathway. In cell culture, zebrafish, and mouse models, the combination of the two drugs was more effective than each treatment alone at killing leukaemia cells. According to the researchers, a new drug screening approach for the rapid assessment of treatment responses in leukaemia samples was developed and optimised in a zebrafish T-ALL model throughout the inquiry. This search led to the discovery of an effective medicine combination, which was later confirmed by various cell line models, patient samples, and mouse models," says PhD Saara Laukkanen, the study's first author. As a result of this four- to five-year study, we now know the molecular mechanism of action of these medicines in T-ALL. She worked on the study as a Visiting Researcher at Harvard Stem Cell Institute in Boston for six months, where she collaborated with Professor David Langenau's research group. This is a potential new T-acute leukaemia therapeutic option. The next step is to use early phase clinical studies to translate the discovery into clinical practise for individuals with relapsed or refractory illness. Precision medicine takes time to develop because it necessitates a thorough understanding of the molecular pathways that create and perpetuate illness. "We used a unique T-ALL cell reliance on certain signalling channels that the combination of dasatinib and temsirolimus shuts off," Lohi explains. Blood, the most famous scholarly magazine in the field of haematology, published the findings. Experts from the Universities of North Carolina, Eastern Finland, and Helsinki, as well as Tampere University and Harvard Stem Cell Institute researchers, took part in the study.

Reference: -